Cooley M&A

JANUARY 23, 2024

Strategic innovation Strategic acquirers are feeling more pressure to consummate bolt-on acquisitions in order to round out their portfolios, enter new markets and fill innovation gaps. Moving into Q2 of 2023, roughly 29% of US public biotech companies traded below their cash value.

M&A 52

M&A Mergers and Acquisitions Pharmaceutical Acquisitions 52

Growth Business

SEPTEMBER 13, 2023

Investment range: £50,000 – £3m Sectors: fintech, insurtech, regtech, digital health and medical technology, artificial intelligence and machine learning, consumer services, digital media, semiconductors and displays, cybersecurity, enterprise software, autonomous systems and human computer interfaces, novel materials and quantum technology.

Capital 52

Capital Business Funds Investment 52

Cooley M&A

JANUARY 25, 2024

In one of the most high-profile examples of this increased scrutiny, the US Federal Trade Commission (FTC) attempted to block Horizon Therapeutics’ $29.3 Out of the Nordic countries, companies such as Novo Nordisk capitalized on massive revenue boosts from weight-loss medications (Wegovy and Ozempic) with multibillion-dollar acquisitions.

M&A 52

M&A Mergers and Acquisitions Government Investment 52

Cooley M&A

JANUARY 25, 2023

Similarly, we expect sponsors to actively pursue carve out opportunities – like Francisco Partners’ carve out acquisition of the data and analytics assets from IBM’s Watson Health business – in 2023 as tech giants streamline their portfolios to focus on their core businesses.

M&A 52

M&A Mergers and Acquisitions Private Equity Mergers 52

Cooley M&A

JANUARY 20, 2022

approved prescription cannabidiol medicine to its portfolio. For example, early in 2021, Zimmer Biomet Holdings announced that it would spin off its spine and dental businesses into a new publicly traded company as a way to “optimize resource allocation” among its remaining businesses. driven assets.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Mergers 40

Focus Investment Banking

FEBRUARY 11, 2025

Overcoming Marketplace Uncertainty Rising interest rates introduced a difficult environment for private equity recapitalizations (where private equity groups sell a portfolio company to another buyer), so few of the older PE-backed ophthalmology organizations traded hands over the last few years. dental).

Private Equity 52

Private Equity Healthcare Equities Medical 52

Mergers and Inquisitions

MARCH 5, 2025

Example Biotech Trades What Makes Biotech Hedge Funds Different? Many biotech stocks are relatively uncorrelated with the broader market because they trade based on catalysts rather than GDP growth, inflation, interest rates, or consumer spending. Of course, many other trades are possible. And What Do They Do?

Funds 64

Funds Healthcare Mergers and Acquisitions Valuation 64